Transplants

Antibodies halve rejection risk

Birmingham, UK - Giving interleukin-2 receptor antibodies to patients after a kidney transplant can halve the risk of rejection, according to a study published in the British Medical Journal (Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials BMJ Volume 326, pp 789-91).

Photo: Transplants

Consultant Nephrologist Dwomoa Adu, and a team of researchers at the Nephrology Department, Queen Elizabeth Hospital, reviewed eight trials of interleukin-2 receptor antibodies versus placebo in 1,858 patients receiving standard immunosuppressant drugs after kidney transplants.
Treatment with interleukin-2 receptor antibodies reduced the risk of acute rejection by 49% after six months. Patients receiving antibodies did not have an increased risk of infection, and there were no significant differences in the rate of graft loss or survival after one year.

Reducing the rate of acute rejection is important in kidney transplantation, as patients who have had one or more episodes of acute rejection have at least a 50% reduction in long term graft survival, say the authors. They conclude that longer follow up studies are needed to confirm whether interleukin-2 receptor antibodies improve long term graft and patient survival.

Contact: dwomoa.adu@uhb.nhs.uk

30.04.2003

More on the subject:
Read all latest stories

Related articles

Photo

News • Organ preservation

Perfusion machine takes time pressure off liver transplantation

A special perfusion machine preserves donor livers for an extended period of time without compromising organ quality. New Dutch research has confirmed the safety of the procedure for recipients.

Photo

News • Stem cell research

Camouflaging transplants to avoid immune rejection

Researchers from the Chinese Academy of Sciences, Beijing, have genetically engineered stem cells so that liver cells obtained from them would be invisible to the immune system.

Photo

News • Extracorporeal photopheresis

Study on ECP in heart transplant patients presents promising results

Results from a large European study reinforce the use of Extracorporeal photopheresis (ECP) in heart transplant patients as a treatment for heart transplant rejection and prevention of rejection.

Related products

Subscribe to Newsletter